Last reviewed · How we verify
sevelamer carbonate oral tablet
At a glance
| Generic name | sevelamer carbonate oral tablet |
|---|---|
| Also known as | Renvela |
| Sponsor | SIGA Technologies |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia (PHASE2)
- Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (PHASE4)
- Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China (PHASE3)
- Head to Head Study Against Sevelamer Hydrochloride (PHASE3)
- Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat (PHASE1)
- Sevelamer for Reducing Endotoxemia and Immune Activation (PHASE2)
- An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients (PHASE3)
- An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |